MedPath

Rheumatoid Arthritis Real-world Cohort Study in China (ReALSA)

Not yet recruiting
Conditions
Rheumatoid Arthritis
Registration Number
NCT06233929
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brief Summary

An ongoing long-term cohort study is conducted in the Sun Yat-sen Memorial Hospital of Sun Yat-sen University, that is dedicated to recruiting RA patients, to identify the development of clinical, neuroimaging, and biochemical biomarkers for the diagnosis and prognosis of RA, especially for those with sarcopenia/myopenia

To improve the prognosis of RA, this study includes the following objectives:

1. Construct a useful database to explore the secular dynamic progress of RA, especially the difference between early and lately RA, as well as to improve our understanding of the life-course factors affecting the process that will facilitate future research activities.

2. Identify the potential markers (clinical, biomedical and imaging) affecting/predicting the development process of sarcopenia/myopenia or other prognosis in RA patients.

3. Develop the related multi-modal prediction models with clinical, biomedical and imaging variables to improve the diagnosis and prognosis of RA.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • Patients aged 18 years or older and diagnosed with RA according to 1987 ACR or 2010 ACR / EULAR classification criteria
Exclusion Criteria
  • Patients diagnosis with tumors without control, or AIDS
  • Patients with serious disease in cardiovascular, kidney and blood and endocrine system; and 3) history of schizophrenia or epilepsy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Myopenia10 years

Myopenia was defined by an ASMI≤ 7.0 kg/m2 in men and≤ 5.7 kg/m2 in women according to the Asian Working Group for Sarcopenia (AWGS)

CVDs10 years

CVDs were defined as a verified medical history of angina pectoris, myocardial infarction, heart failure, ischemic or hemorrhagic stroke, and peripheral arterial disease \[17\], which was verified through a questionnaire survey and confirmation by medical record

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath